| NATIONAL DEFENSE MEDICAL CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129175 | METHOD FOR RENAL DISEASE DIAGNOSIS AND PROGNOSIS USING ANNEXIN A1 AND RAB23 AS MARKERS - Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. | 05-24-2012 |
| 20120101157 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof - Disclosed are 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and manufactures thereof. The 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives are presented by formula (I): | 04-26-2012 |
| 20120088810 | THIOXANTHONE RING SYSTEM DERIVATIVES - A thioxanthone ring system derivative compound is provided. The thioxanthone ring system derivative compound is represented by a formula (I): | 04-12-2012 |
| 20110287452 | Test Kit for Detecting Klebsiella Pneumoniae Serotype K1 and Method Using Same - Disclosed are a test kit and method for sensitively and rapidly detecting | 11-24-2011 |
| 20110224218 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS - A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (IV): | 09-15-2011 |
| 20110183349 | BIOMARKERS FOR IgA NEPHROPATHY AND APPLICATIONS THEREOF - The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof. | 07-28-2011 |
| 20110124721 | METHODS OF TREATING TRAUMATIC BRAIN INJURY BY ADMINISTERING BAICALEIN PREPARATION - The invention provides a novel medical use of Baicalein, and in particular, a use of baicalein in the preparation of a pharmaceutical composition useful for treating traumatic brain injury. The baicalein pharmaceutical composition in this invention includes a treating effective amount of baicalein and a suitable pharmaceutically acceptable excipient or carrier. The baicalein pharmaceutical composition is applicable for improving the behaviour function deficit in traumatic brain injury, reducing the contusion volume of traumatic brain injury, improving the brain neuronal degeneration in traumatic brain injury, reducing proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) or other relative inflammation factor induced in traumatic brain injury. | 05-26-2011 |
| 20100249143 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS - A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): | 09-30-2010 |
| 20100222421 | Usage of Baicalein in the Preparation of a Pharmaceutical Composition for the Treatment of Traumatic Brain Injury - The invention provides a novel medical use of Baicalein, and in particular, a use of baicalein in the preparation of a pharmaceutical composition useful for treating traumatic brain injury. The baicalein pharmaceutical composition in this invention includes a treating effective amount of baicalein and a suitable pharmaceutically acceptable excipient or carrier. The baicalein pharmaceutical composition is applicable for improving the behaviour function deficit in traumatic brain injury, reducing the contusion volume of traumatic brain injury, improving the brain neuronal degeneration in traumatic brain injury, reducing proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) or other relative inflammation factor induced in traumatic brain injury. | 09-02-2010 |
| 20100203512 | METHOD FOR RENAL DISEASE DIAGNOSIS AND PROGNOSIS USING ANNEXIN A1 AND RAB23 AS MARKERS - Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. | 08-12-2010 |
| 20100081142 | BIOMARKERS FOR KIDNEY DISEASES AND METHOD FOR USING SAME - The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis. | 04-01-2010 |
| 20100016309 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same - The invention provides a type of novel 1,2,3,4-tetrahydroisoquinoline derivatives with a structure of formula (I): | 01-21-2010 |
| 20090253709 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES - An series of 2,7-disubstituted anthraquinone derivatives including a formula I are provided. | 10-08-2009 |
| 20090253707 | HETEROANNELATED ANTHRAQUINONE DERIVATIVES AND THE SYNTHESIS METHOD THEREOF - A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): | 10-08-2009 |
| 20080311570 | CANCER SCREENING METHOD - A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing. | 12-18-2008 |
